Bioasis to Attend and Present at Upcoming Industry Conferences
09 Décembre 2021 - 10:30PM
BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF),
(the “Company” or “Bioasis”), a biopharmaceutical company
developing its proprietary xB3™ platform technology for the
delivery of therapeutics across the blood-brain barrier (“BBB”) and
the treatment of central nervous system (“CNS”) disorders in areas
of high unmet medical need, including brain cancers and
neurodegenerative diseases, is pleased to announce that Dr. Deborah
Rathjen, Executive Chair will be attending and presenting at the
following industry conferences:
- H.C. WAINWRIGHT BIOCONNECT
VirtualJanuary 10-13, 2022
- BIOTECH SHOWCASE
DigitalJanuary 17-19, 2022
On behalf of the Board of Directors of Bioasis
Technologies Inc.Deborah Rathjen, Ph.D., Executive Chair
of the Board
Follow on:FacebookInstagramLinkedInTwitter
BTI-E&P
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company
developing the xB3™ platform, a proprietary technology for the
delivery of therapeutics across the blood brain barrier and the
treatment of CNS disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases. The
delivery of therapeutics across the blood brain barrier represents
the final frontier in treating neurological disorders. The in-house
development programs at Bioasis are designed to develop symptomatic
and disease-modifying treatments for brain-related diseases and
disorders. For more information about the Company, please visit
www.bioasis.us.
Forward Looking Statements
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact along with other statements containing the words “believe,”
“may,” “plan,” “will,” “estimate,” “continue,” “anticipate,”
“intend,” “expect” and similar expressions. Such forward-looking
statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
events or developments, or industry results, to be materially
different from any future results, events or developments express
or implied by such forward-looking statements or information. Such
factors include, among others, our stage of development, lack of
any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining
regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and
the prospects for negotiating additional corporate collaborations
or licensing arrangements and their timing. Specifically, certain
risks and uncertainties that could cause such actual events or
results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include,
but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials,
or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not
be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing
arrangements; we may not be able to establish marketing and the
costs of launching our products may be greater than anticipated; we
have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and
other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release
Contacts:
Deborah Rathjen, Ph.D., Executive Chair of the Board and
CEOdeborah@bioasis.us203-533-7082
Investor Contact:Graeme DickColwell Capital
Corp.graeme@colwellcapital.com403-561-8989
BiOasis Technologies (TSXV:BTI)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
BiOasis Technologies (TSXV:BTI)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025